News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
An accomplished R&D leader and champion of the application of AI to drug discovery
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Subscribe To Our Newsletter & Stay Updated
